|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/04 | (2006.01) |
| A61K 31/4439 | (2006.01) | ||
| A61K 31/4184 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3533792 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19169275.5 |
| Date of filing the European patent application | 2013-06-04 | |
| (97) | Date of publication of the European application | 2019-09-04 |
| (45) | Date of publication and mention of the grant of the patent | 2021-05-05 |
| (46) | Date of publication of the claims translation | 2021-07-26 |
| (30) | Number | Date | Country code |
| 201261656888 P | 2012-06-07 | US |
| (72) |
DILHAS, Anna, CH
OUERFELLI, Ouathek, US
SMITH, Nicholas D., US
HERBERT, Mark R., US
|
| (73) |
Sloan Kettering Institute For Cancer Research,
1275 York Avenue, New York, NY 10065,
US
Aragon Pharmaceuticals, Inc. , 10990 Wilshire Blvd. Suite 440, Los Angeles, CA 90024, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Androgeno receptoriaus moduliatoriaus kristalinės formos |
| CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR |
| Payment date | Validity (years) | Amount | |
| 2025-05-05 | 13 | 289.00 EUR |
| 2026-06-04 |